Proteomic approaches in brain research and neuropharmacology.
Numerous applications of genomic technologies have enabled the assembly of unprecedented inventories of genes, expressed in cells under specific physiological and pathophysiological conditions. Complementing the valuable information generated through functional genomics with the integrative knowledge of protein expression and function should enable the development of more efficient diagnostic tools and therapeutic agents. Proteomic analyses are particularly suitable to elucidate posttranslational modifications, expression levels and protein-protein interactions of thousands of proteins at a time. In this review, two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) investigations of brain tissues in neurodegenerative diseases such as Alzheimer's disease, Down syndrome and schizophrenia, and the construction of 2D-PAGE proteome maps of the brain are discussed. The role of the Human Proteome Organization (HUPO) as an international coordinating organization for proteomic efforts, as well as challenges for proteomic technologies and data analysis are also addressed. It is expected that the use of proteomic strategies will have significant impact in neuropharmacology over the coming decade.
Douglas Hospital Research Center, Institute of Neuroscience, Mental Health and Addiction, Department of Neurology and Neurosurgery, McGill University, 6875 LaSalle Boulevard, Montréal, Quebec, Canada.
Freya G G
FG
Vercauteren
John J M
JJ
Bergeron
Frans
F
Vandesande
Lut
L
Arckens
Rémi
R
Quirion
D000544:Alzheimer Disease / Q000235:genetics; D000818:Animals; D001921:Brain / Q000502:physiology*; D004314:Down Syndrome / Q000235:genetics; D006801:Humans; D019636:Neurodegenerative Diseases / Q000235:genetics; D009480:Neuropharmacology / Q000379:methods*; D040901:Proteomics; D012559:Schizophrenia / Q000235:genetics